GlassScriptPhysician profile
Victoria Mccarver
NPI 1831650928
$782.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.86 · 2021: $143 · 2022: $527 · 2023: $66.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $186.10 | 2022 | |
| Abbvie INC. | $145.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $101.41 | 2021 | |
| Dermavant Sciences, INC. | $96.80 | 2022 | |
| Journey Medical Corporation | $42.01 | 2021 | |
| Sun Pharmaceutical Industries INC. | $37.81 | 2022 | |
| Ucb, INC. | $37.59 | 2023 | Cimzia |
| Helsinn Therapeutics (U.S.), INC. | $27.75 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.28 | 2022 | |
| Kyowa Kirin, INC. | $20.81 | 2022 | |
| Epi Health, LLC | $17.11 | 2020 | |
| Amgen INC. | $16.52 | 2023 | Otezla, Enbrel |
| Sebela Pharmaceuticals INC. | $15.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.84 | 2023 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Mccarver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.